MagForce AG Installs NanoActivator(r) at the University Hospital Munster

BERLIN, Germany, Nov. 6, 2013 (GLOBE NEWSWIRE) --

MagForce AG (Frankfurt, Xetra: MF6), a medical technology company that focuses on the field of oncology and is a leader in the nanotechnology sector, today announced the installation of the second NanoActivator®. The NanoActivator® was brought into operation as part of the preparations for the new glioblastoma study at the University Hospital Münster and is the second after the one at the university hospital Charité in Berlin. Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery and Neurooncology at the University Hospital Münster and head of the new clinical trial, said: "I am extremely happy to say that my center now has its own NanoActivator® and we can commence recruitment into this important study in neuro-oncology. We anticipate a significant added value to the technology once we have more experience in its use for therapy and are eager for generating additional data on efficacy from a randomized study. We are continually in contact with the clinical team at MagForce AG for directly communicating current developments in the progress of the study." Prof. Dr. Hoda Tawfik, CMO/COO of MagForce AG: "Since the start of considerations about a new glioblastoma study, we have been in close contact with important medical opinion leaders in neurooncology. They contributed significantly to the creation of the study design. With the installation of another NanoActivator®, we are an important step closer to introducing this therapy to the medical community. Our goal is to take NanoTherm(®) therapy to the next level and to corroborate previous clinical results." The new glioblastoma study aims to validate the previous results of NanoTherm® therapy in direct comparison to currently available standard therapy in a larger patient pool. This will allow the company to draw meaningful conclusions about the potential of this new approach to treating patients with glioblastomas. The patients recruitment in this new glioblastoma study will start end of 2013. Until then, a total of three NanoActivators® are planned to be set up and operational. Additional centers will follow in 2014. About MagForce AG MagForce AG is a leading medical device company in the field of nanomedicine in oncology, listed in the entry standard (MF6). The Company's proprietary, NanoTherm(®) therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(®), NanoPlan(®), and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(®), NanoPlan(®), and NanoActivator® are trademarks of MagForce AG in selected countries. For more information, please visit Disclaimer This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward- looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. Contact: Anne Hennecke MC Services AG T +49 89 210228-18 F +49 89 210228-88 M +49 151 12 555 759 Email: MagForce_PRess Release_Nov 06, 2013: [HUG#1740916] Source:MagForce AG